| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 03/28/2002 | WO2002024214A2 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 03/28/2002 | WO2002024196A1 Iron compositions |
| 03/28/2002 | WO2002000266A3 A method of treating and preventing infectious diseases |
| 03/28/2002 | WO2001094952A3 Methods and compositions for modulating oxidized ldl transport |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001072279A3 Medical emulsion for lubrication and delivery of drugs |
| 03/28/2002 | WO2001070977A3 Fibroblast growth factor receptor-like molecules and uses thereof |
| 03/28/2002 | WO2001055357A3 Myeloid colony stimulating factor and uses thereof |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | US20020037933 Sterile pharmaceutical for parenteral administration which comprises the compound 2,6-diisopropylphenol (propofol) with a sterile diluent or carrier; counteracting endotoxin induced deterioration of arterial oxygen tension |
| 03/28/2002 | US20020037912 Factor viia inhibitors |
| 03/28/2002 | US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/28/2002 | US20020037874 Anticoagulants |
| 03/28/2002 | US20020037852 Anticarcinogenic agents |
| 03/28/2002 | US20020037848 Alzheimer's disease; Parkinson's disease |
| 03/28/2002 | US20020037841 Blood disorders; drug in aqueous solution |
| 03/28/2002 | US20020037836 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| 03/28/2002 | US20020037549 ABC transport polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037329 Biochemically balanced peritoneal dialysis solutions |
| 03/28/2002 | US20020035996 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| 03/28/2002 | DE10046272A1 New biphenyl-substituted amino-(iso)quinoline derivatives, are factor Xa and factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, angina pectoris or restenosis |
| 03/28/2002 | CA2424576A1 Efficient process for the preparation of a factor xa inhibitor |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2423058A1 Polypeptide having phospholipase a2 activity |
| 03/28/2002 | CA2422560A1 4-amino-quinazolines |
| 03/28/2002 | CA2422488A1 4-amino-quinazolines |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/28/2002 | CA2416136A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/27/2002 | EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2002 | EP1191028A1 Tricyclic compounds having spiro union |
| 03/27/2002 | EP1190716A1 The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof |
| 03/27/2002 | EP1190714A2 Method for the treatment of thromboembolic disorders in patients with aspirin resistance |
| 03/27/2002 | EP1190249A2 Compounds and methods to enhance raav transduction |
| 03/27/2002 | EP1190086A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 03/27/2002 | EP1190082A1 Method of inducing angiogenesis by micro-organs |
| 03/27/2002 | EP1190074A1 Recombinant anti-cd40 antibody and uses thereof |
| 03/27/2002 | EP1190072A2 22012, a novel human carboxypeptidase |
| 03/27/2002 | EP1190052A1 16405 receptor, a g-protein coupled receptor |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1189942A1 Somatostatin agonists |
| 03/27/2002 | EP1189941A1 Neuromedin b and somatostatin receptor agonists |
| 03/27/2002 | EP1189930A1 INHIBITORS OF THE INTEGRIN AlPHA V BETA 6 |
| 03/27/2002 | EP1189929A2 Factor viia inhibitors |
| 03/27/2002 | EP1189922A1 Steroid derivatives |
| 03/27/2002 | EP1189917A1 48 human secreted proteins |
| 03/27/2002 | EP1189916A2 N-pyrazole a 2a receptor agonists |
| 03/27/2002 | EP1189901A1 Oxazaheterocycles as protease inhibitors |
| 03/27/2002 | EP1189899A1 Pyrazinone thrombin inhibitors |
| 03/27/2002 | EP1189895A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 03/27/2002 | EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS |
| 03/27/2002 | EP1189883A2 Substituted pyrrolidines as cell adhesion inhibitors |
| 03/27/2002 | EP1189881A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 03/27/2002 | EP1189879A1 INHIBITORS OF FACTOR Xa |
| 03/27/2002 | EP1189663A2 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 03/27/2002 | EP1189623A2 Method and composition for inhibiting cardiovascular cell proliferation |
| 03/27/2002 | EP1189618A1 Thrombin inhibitors |
| 03/27/2002 | EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| 03/27/2002 | EP1189605A2 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof |
| 03/27/2002 | EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 03/27/2002 | EP1189583A1 Indole derivatives |
| 03/27/2002 | EP0820287B1 Thrombin inhibitors |
| 03/27/2002 | EP0792153B1 Compositions containing lazaroids and their use for preventing adhesions |
| 03/27/2002 | CN1342202A Soluble receptor BR43X2 and methods for using them for therapy |
| 03/27/2002 | CN1342167A Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 03/27/2002 | CN1342148A Pyrazole-3-derivative as factor Xa inhibitors |
| 03/27/2002 | CN1342147A NItroxyderivatives having antiinflammatory, analgesic and antithrombotic activity |
| 03/27/2002 | CN1342139A Serine protease inhibitors |
| 03/27/2002 | CN1342084A Therapeutic compositions containing glutathione analogs |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1081642C Method of producing starch decomposition products |
| 03/26/2002 | US6362322 Conversion of a watson-crick DNA to a hoogsteen-paired duplex |
| 03/26/2002 | US6362214 Thermodynamically stable form of (R)-3-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (ramatroban) |
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6361997 Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy |
| 03/26/2002 | US6360651 Home-style decoctor endowed with steamy boiling function, and method of preparing red ginseng extract using the same |
| 03/21/2002 | WO2002023190A2 Methods and products related to low molecular weight heparin |
| 03/21/2002 | WO2002022832A1 A cell line expressing mutated human tissue - type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein |
| 03/21/2002 | WO2002022776A2 Human coagulation factor vii variants |
| 03/21/2002 | WO2002022621A2 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 03/21/2002 | WO2002022620A2 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022585A1 Tetrahydroquinoline compounds |
| 03/21/2002 | WO2002022575A1 Amidine inhibitors of serine proteases |
| 03/21/2002 | WO2002022571A2 Compounds and methods for inhibiting alpha-1 beta-1 integrins |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| 03/21/2002 | WO2002022150A2 Medicament containing activated antithrombin iii |
| 03/21/2002 | WO2002022143A1 A pharmaceutical composition for treating headache disease and process and uses thereof |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2001098324A8 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |